3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
3
Phase NA
1
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
3
Interventions
Prednisone
54
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
30
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
19
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
18
abiraterone
16
Radiation
15
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
10
cabazitaxel
9
Radiosurgery
9
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
ZD4054
×
Clear all
NCT00554229
2016-02-08
ENTHUSE M1
AstraZeneca
Phase 3
Completed
896 enrolled
15 charts
NCT00617669
2012-09-10
ENTHUSE M1C
AstraZeneca
Phase 3
Completed
1,494 enrolled
14 charts
NCT00626548
2012-09-03
ENTHUSE M0
AstraZeneca
Phase 3
Terminated
2,577 enrolled
8 charts